Alkermes Starts Phase 2 Study of ALKS 7290 for Depression
The study will evaluate the orexin 2 receptor agonist as an adjunctive treatment for major depressive disorder.
Related stories
Harris Teeter Launches New Rewards World Elite Mastercard
The new card offers grocery savings and fuel discounts when shopping at Harris Teeter.
M impact | EQUITY | Oct 30, 2026, 12:01 PM UTC
Palo Alto Networks Advises Stockholders to Reject Tutanota Mini-Tender Offer
Palo Alto Networks said it received notice of an unsolicited offer by Tutanota LLC to buy up to 250,000 shares of its common stock.
H impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
Dominion Energy Q3 Profit Rises to $1.160 Billion
Dominion Energy reported earnings of $1.30 per share, compared with $1.16 per share a year earlier. Profit totaled $1.160 billion, versus $1.006 billion.
M impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
Simon Subsidiary Agrees to Acquire University Village
Simon said a subsidiary entered into an agreement to acquire University Village, an open-air retail property.
M impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
European session market picture: S&P 500 -1.11%, Nasdaq 100 -2.59%; EUR/USD +0.14%, WTI +2.01%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 1.11 percent, Nasdaq futures is down 2.59 percent, Dow futures is up 0.01 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
Exxon Mobil Raises Stake in Mozambique LNG Project to 50%
Exxon Mobil increased its stake in the planned project.
M impact | EQUITY | Oct 30, 2026, 11:58 AM UTC